Home › Alcohol Use Disorder (AUD) › NCT06584448
Drinking, Acetate, and Stress
Role of Acetate in Heavy Drinking
Who can join
Ages 18 to 60 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Medically stable male or female, aged 18-55. * Able to read, write and complete a multitude of self-assessments in English * Meets DSM-5 criteria for current Alcohol Use Disorder (AUD) * Participants who have Alcohol Use Disorder and are actively drinking must be willing to receive (at no cost) inpatient treatment for AUD for a period of up to 30 days. Participants who have been treated for an Alcohol Use Disorder and are now sober three months or longer will NOT be required to go inpatient. Exclusion Criteria: * Subjects with any significant current medical conditions (neurological, cardiovascular, endocrine, thyroid, renal, liver), seizures (for LTS subjects only- seizures directly related to alcohol detoxification are not an exclusion) , delirium or hallucinations, or other unstable medical conditions, including HIV. * Current DSM-5 substance use disorder (other than AUD or tobacco use disorder) * Any metallic objects implanted in their body which would make imaging unsafe (pacemaker, etc) * Claustrophobia, or other inability to participate in an MRI * A positive test result at intake appointment and subsequent appointments on urine drug screens conducted for illicit drugs. (Note: participants will not be paid for study visits if they test positive for an illicit drug and will be immediately excluded from study). * Women who are pregnant or nursing. Women who have an IUD that would make imaging unsafe. * Recent taking of medications that may influence study outcomes (e.g., disulfiram, naltrexone, acamprosate, anticonvulsants). * Subjects likely to exhibit clinically significant alcohol withdrawal during the study.
About the study
The purpose of this study is to learn how drinking alcohol affects how people experience stress and how that is affected by the body's chemistry. Specifically, the investigators will be studying relationships of drinking and a stress hormone called cortisol. The investigators believe that results will lead us to find more effective ways to help people stop or reduce drinking when participants are drinking at harmful levels.
What is being tested
- Deuterium Metabolic Imaging with deuterated acetate tracer (other)
Sponsor: Yale University · Participants: 50 · Started: Nov 6, 2024
Contact the study team
- Graeme Mason, Ph.D. · Phone: 203-737-1478
- Luz Catarineau · Phone: 475-375-6141
Official record on ClinicalTrials.gov — NCT06584448
Locations in the U.S.
| Connecticut | The Anlyan Center, 300 Cedar St., New Haven Yale University, New Haven (Not yet recruiting) |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.